Company Website: http://kmllp.com
NEW YORK -- (Business Wire)

The law firm of Kirby McInerney LLP announced today that a class action lawsuit has been filed in the United States District Court for the District of New Jersey against Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (Nasdaq: FOLD) on behalf of all investors who acquired Amicus securities during the period from March 19, 2015 through October 1, 2015 (the “Class Period”). Pursuant to applicable law, investors have until December 7, 2015 to seek appointment as lead plaintiff in the investor lawsuit.

The lawsuit alleges that throughout the Class Period, the Company issued false and misleading statements regarding the approval status of its lead product candidate Galafold. Amicus represented, among other things, that the FDA had issued positive news regarding the Company’s new drug application (“NDA”) for Galafold, and that the NDA was on track for filing in the fourth quarter of 2015.

The lawsuit also alleges that on October 2, 2015, Amicus reversed course and stated that the FDA news was not positive. Additionally, the Company disclosed that it would not be able to submit its NDA in the fourth quarter of 2015. Following these disclosures Amicus’ stock price declined materially.

If you acquired Amicus securities during the Class Period and you are interested in learning more about this matter and any rights you might have with respect to these claims, contact Rona Li or Daniel Bialer at securitiescases@kmllp.com, or by telephone at (212) 371-6600. Please bear in mind that some of these rights may be time-sensitive.

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, whistleblower, antitrust and consumer litigation. The firm has specialized in securities class actions, for several decades. Kirby McInerney LLP has repeatedly demonstrated its expertise in this field, and has been recognized by various courts that have appointed the firm to major positions in such suits. The firm's efforts in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm or the claims against Amicus Therapeutics, Inc. can be found at Kirby McInerney LLP's website: http://www.kmllp.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151009005685/en/

Contacts:

Kirby McInerney LLP
Rona Li or Daniel Bialer, (212) 371-6600
securitiescases@kmllp.com

Source: Kirby McInerney LLP